doi: 10.1124/pr.115.011395 111 BullockBPHellerRSHabenerJF
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The American Diabetes Association (ADA) uses results of blood tests as the diagnostic criteria
Collectively referred to as GLP-1s, these medications have been used to treat type 2 diabetes for about two decades
GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024) GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar evaluated the evidence for GLP-1Rs role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions
No needles